Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma

Stephan Rehn; Khaled Elsayad; Michael Oertel; Andrea Baehr; Nicole Eter; Uwe Haverkamp; Georg Lenz; Hans Theodor Eich

doi:10.21873/anticanres.14400

Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma

Standard

Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma. / Rehn, Stephan; Elsayad, Khaled; Oertel, Michael; Baehr, Andrea; Eter, Nicole; Haverkamp, Uwe; Lenz, Georg; Eich, Hans Theodor.

in: ANTICANCER RES, Jahrgang 40, Nr. 7, 07.2020, S. 4041-4046.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rehn, S, Elsayad, K, Oertel, M, Baehr, A, Eter, N, Haverkamp, U, Lenz, G & Eich, HT 2020, 'Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma', ANTICANCER RES, Jg. 40, Nr. 7, S. 4041-4046. https://doi.org/10.21873/anticanres.14400

APA

Rehn, S., Elsayad, K., Oertel, M., Baehr, A., Eter, N., Haverkamp, U., Lenz, G., & Eich, H. T. (2020). Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma. ANTICANCER RES, 40(7), 4041-4046. https://doi.org/10.21873/anticanres.14400

Vancouver

Rehn S, Elsayad K, Oertel M, Baehr A, Eter N, Haverkamp U et al. Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma. ANTICANCER RES. 2020 Jul;40(7):4041-4046. https://doi.org/10.21873/anticanres.14400

Bibtex

@article{4103a74e8fe2434aacfb49b3ae6ada7a,

title = "Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma",

abstract = "AIM: Modern radiotherapy (RT) technique and therapy de-escalation have led to encouraging results in lymphoma management. In this study, we aimed to describe the oncological and toxicity outcome in patients with ocular adnexal lymphoma.PATIENTS AND METHODS: A total of 45 patients with 52 orbital lesions who were treated at our Institution between 2003 and 2019 were considered. Clinical characteristics, treatment outcomes, and toxicity were assessed. Patients receiving 4-6 Gy were categorized as receiving ultra-low-dose RT, 24-30.6 Gy as standard-dose RT, and >30.6 Gy as high-dose RT.RESULTS: The predominant histological subtype was marginal zone lymphoma in 39 lesions (75%). Radiation dose ranged from 4-50.4 Gy. In the whole cohort, 11% of the lesions were treated with ultra-low-dose RT, 33% with standard-dose RT, and 56% with high-dose RT; 60% of lesions were treated using intensity-modulated RT (IMRT), while 44% of lesions were treated with partial orbital RT. The median duration of follow-up was 33 months. The overall response rate was 94% (complete response rate=83%). The 5-year local control rate, progression-free survival, and overall survival were 100%, 76%, and 92%, respectively. We did not detect any significant difference in progression-free or overall survival regarding different radiation doses and volumes. Ultra-low-dose RT was associated with a significantly lower rate of grade 2 late toxicities (0% vs. 6% and 31%, p=0.05) in comparison with standard-dose and high-dose RT, respectively. Patients who received IMRT had a significant fewer acute grade 2 (16% vs. 43%, p=0.05) and a trend towards lower late grade 2 toxicities (9% vs. 33%, p=0.06).CONCLUSION: Radiation dose and volume de-escalation seem to be safe and effective, with excellent local control and survival in the management of ocular adnexal lymphoma. IMRT seems to be associated with less toxicity.",

keywords = "Adult, Aged, Aged, 80 and over, Eye Neoplasms/radiotherapy, Female, Humans, Lymphoma/radiotherapy, Male, Middle Aged, Radiotherapy Dosage",

author = "Stephan Rehn and Khaled Elsayad and Michael Oertel and Andrea Baehr and Nicole Eter and Uwe Haverkamp and Georg Lenz and Eich, {Hans Theodor}",

year = "2020",

month = jul,

doi = "10.21873/anticanres.14400",

language = "English",

volume = "40",

pages = "4041--4046",

journal = "ANTICANCER RES",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "7",

}

RIS

TY - JOUR

T1 - Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma

AU - Rehn, Stephan

AU - Elsayad, Khaled

AU - Oertel, Michael

AU - Baehr, Andrea

AU - Eter, Nicole

AU - Haverkamp, Uwe

AU - Lenz, Georg

AU - Eich, Hans Theodor

PY - 2020/7

Y1 - 2020/7

N2 - AIM: Modern radiotherapy (RT) technique and therapy de-escalation have led to encouraging results in lymphoma management. In this study, we aimed to describe the oncological and toxicity outcome in patients with ocular adnexal lymphoma.PATIENTS AND METHODS: A total of 45 patients with 52 orbital lesions who were treated at our Institution between 2003 and 2019 were considered. Clinical characteristics, treatment outcomes, and toxicity were assessed. Patients receiving 4-6 Gy were categorized as receiving ultra-low-dose RT, 24-30.6 Gy as standard-dose RT, and >30.6 Gy as high-dose RT.RESULTS: The predominant histological subtype was marginal zone lymphoma in 39 lesions (75%). Radiation dose ranged from 4-50.4 Gy. In the whole cohort, 11% of the lesions were treated with ultra-low-dose RT, 33% with standard-dose RT, and 56% with high-dose RT; 60% of lesions were treated using intensity-modulated RT (IMRT), while 44% of lesions were treated with partial orbital RT. The median duration of follow-up was 33 months. The overall response rate was 94% (complete response rate=83%). The 5-year local control rate, progression-free survival, and overall survival were 100%, 76%, and 92%, respectively. We did not detect any significant difference in progression-free or overall survival regarding different radiation doses and volumes. Ultra-low-dose RT was associated with a significantly lower rate of grade 2 late toxicities (0% vs. 6% and 31%, p=0.05) in comparison with standard-dose and high-dose RT, respectively. Patients who received IMRT had a significant fewer acute grade 2 (16% vs. 43%, p=0.05) and a trend towards lower late grade 2 toxicities (9% vs. 33%, p=0.06).CONCLUSION: Radiation dose and volume de-escalation seem to be safe and effective, with excellent local control and survival in the management of ocular adnexal lymphoma. IMRT seems to be associated with less toxicity.

AB - AIM: Modern radiotherapy (RT) technique and therapy de-escalation have led to encouraging results in lymphoma management. In this study, we aimed to describe the oncological and toxicity outcome in patients with ocular adnexal lymphoma.PATIENTS AND METHODS: A total of 45 patients with 52 orbital lesions who were treated at our Institution between 2003 and 2019 were considered. Clinical characteristics, treatment outcomes, and toxicity were assessed. Patients receiving 4-6 Gy were categorized as receiving ultra-low-dose RT, 24-30.6 Gy as standard-dose RT, and >30.6 Gy as high-dose RT.RESULTS: The predominant histological subtype was marginal zone lymphoma in 39 lesions (75%). Radiation dose ranged from 4-50.4 Gy. In the whole cohort, 11% of the lesions were treated with ultra-low-dose RT, 33% with standard-dose RT, and 56% with high-dose RT; 60% of lesions were treated using intensity-modulated RT (IMRT), while 44% of lesions were treated with partial orbital RT. The median duration of follow-up was 33 months. The overall response rate was 94% (complete response rate=83%). The 5-year local control rate, progression-free survival, and overall survival were 100%, 76%, and 92%, respectively. We did not detect any significant difference in progression-free or overall survival regarding different radiation doses and volumes. Ultra-low-dose RT was associated with a significantly lower rate of grade 2 late toxicities (0% vs. 6% and 31%, p=0.05) in comparison with standard-dose and high-dose RT, respectively. Patients who received IMRT had a significant fewer acute grade 2 (16% vs. 43%, p=0.05) and a trend towards lower late grade 2 toxicities (9% vs. 33%, p=0.06).CONCLUSION: Radiation dose and volume de-escalation seem to be safe and effective, with excellent local control and survival in the management of ocular adnexal lymphoma. IMRT seems to be associated with less toxicity.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Eye Neoplasms/radiotherapy

KW - Female

KW - Humans

KW - Lymphoma/radiotherapy

KW - Male

KW - Middle Aged

KW - Radiotherapy Dosage

U2 - 10.21873/anticanres.14400

DO - 10.21873/anticanres.14400

M3 - SCORING: Journal article

C2 - 32620650

VL - 40

SP - 4041

EP - 4046

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 7

ER -